News
ONC
230.86
+2.38%
5.37
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
Barchart · 2d ago
BOSTONGENE COLLABORATES WITH BEIGENE TO ADVANCE BIOMARKER DISCOVERY IN MANTLE CELL LYMPHOMA
Reuters · 4d ago
Weekly Report: what happened at ONC last week (0203-0207)?
Weekly Report · 5d ago
BeiGene, Ltd. (NASDAQ:ONC) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Simply Wall St · 02/06 10:15
Weekly Report: what happened at ONC last week (0127-0131)?
Weekly Report · 02/03 09:05
Leap Therapeutics cut to Neutral at Baird after mid-stage trial setback
Seeking Alpha · 01/29 16:37
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene
Dow Jones · 01/29 15:44
ImmunityBio And BeiGene Enter Collaboration For Phase 3 Trial Combining ANKTIVA With Tislelizumab To Improve Survival In NSCLC Patients Resistant To CPI Therapy; ANKTIVA BLA Submission Expected In 2025; Patent Extends To 2035; Study Includes 462 Participants
Benzinga · 01/29 13:32
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism
Barchart · 01/29 12:52
Leap Therapeutics Halts Sirexatamab Combo Therapy For Gastric Cancer ON Unclear Positive Signal, Stock Crashes
Benzinga · 01/28 18:57
Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback
Seeking Alpha · 01/28 13:00
BeiGene’s Strategic Growth and Global Expansion Underpin Buy Rating
TipRanks · 01/27 13:27
Weekly Report: what happened at ONC last week (0120-0124)?
Weekly Report · 01/27 09:05
3 Biotech Stocks With Notable Insider Buying
Seeking Alpha · 01/22 17:29
Weekly Report: what happened at ONC last week (0113-0117)?
Weekly Report · 01/20 09:04
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Benzinga · 01/19 13:33
Netflix, Procter & Gamble, Johnson & Johnson Report Results In Holiday-Shortened Week
Seeking Alpha · 01/18 16:00
Catalyst Watch: Netflix earnings, Monster Beverage event, drug data, and quantum volatility
Seeking Alpha · 01/17 20:00
Hold Rating on BeiGene: Balancing Pipeline Progress with Market Challenges
TipRanks · 01/17 13:25
Baird Q4 2024 International And Global Growth Fund Commentary
Seeking Alpha · 01/17 03:55
More
Webull provides a variety of real-time ONC stock news. You can receive the latest news about Beigene Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ONC
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.